

		Mean	Median (Range)	N	%	n/a (%)
Demographic data	Age (years)	52	53 (21-73)	66		
	Age, men (years)	51	51 (26-71)	26	39	
	Age, women (years)	52	54 (21-73)	40	61	
Asthma	Age at onset (years)	34	33 (3-66)			2 (3)
	Years with phenotype	17	15 (1-48)			
	Set as first diagnosis			38	58	
	Control of disease: good or very good			55	83	3 (5)
	Control of disease: poor or very poor control			8	12	3 (5)
	Positive family history			37	56	8 (12)
	Negative family history			21	32	8 (12)
Nasal polyps	Age at onset (years)	36	34 (11-70)			1 (2)
	Years with phenotype	16	12 (1-45)			
	Set as first diagnosis			10	15	
	Surgical removal of nasal polyps			63	95	
	Control of disease: good or very good			38	58	3 (5)
	Control of disease: poor or very poor control			25	38	3 (5)
	Positive family history			14	21	11 (17)
	Negative family history			41	62	11 (17)
NSAID intolerance	Age at onset (years)	35	35 (5-65)			6 (9)
	Years with phenotype	16	15 (0-46)			
	Set as first diagnosis			7	11	
	NSAID-related symptoms			64	97	2 (3)
	ASA challenge			30	45	
	ASA desensitization			23	35	
	Successful ASA desensitization			12	18	
	Negative family history			40	61	20 (30)
Treatment	Inhaled corticosteroids			62	94	
	Leucotriene modifiers			28	42	
	Biologic medical therapy			2	3	
	Topical nasal steroids			59	89	
	Regular peroral ASA 250 mg			5	8	
	Peroral corticosteroids for asthma †			42	64	3 (5)
	No peroral corticosteroids needed for asthma †			21	32	3 (5)
	Peroral corticosteroids for nasal polyps †			39	59	10 (15)
	No peroral corticosteroids needed for nasal			17	26	10 (15)
Ear symptoms	Control of disease: good or very good			48	73	8 (12)
	Control of disease: poor or very poor control			10	15	8 (12)
	No hearing aid			57	86	5 (8)
	Bilateral hearing aid			4	6	5 (8)